Supplement FactsServing Size:1 Capsule
N-Acetyl-L-Cysteine … 500 mg
Non-medicinal Ingredients: Capsule: hypromellose.
AOR Guarantees: that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, dairy, soy, eggs, fish, shellfish or any animal byproducts.
Source: Pharmaceutical synthesis
What Is It?
N-Acetyl-L-Cysteine, or NAC, is an acetylated form of the amino acid cysteine. Acetylated cysteine is better absorbed than regular cysteine.
What Does It Do?Primary Uses: Cysteine is the most important precursor to glutathione (GSH), the most critical antioxidant produced in the body. Glutathione helps chelate toxins and heavy metals from the body. NAC is approved as a drug in some European jurisdictions for use in preventing liver damage from acetaminophen overdose. NAC has also been used for over 30 years for respiratory health, providing some relief those suffering from chronic respiratory conditions such as the annoying post-nasal drip, sinusitis, chronic bronchitis, the congenital disease cystic fibrosis, and life-threatening conditions such as COPD.
Secondary Uses: NAC also promotes cardiovascular health. NAC has the unique ability to inhibit levels of a specific lipoprotein called Lp(a), an indicator of heart disease. Shown to lower Lp(a) by 70%, NAC is the most effective nutrient known to reduce this heart health risk factor. NAC also prevents the oxidation of LDL (bad) cholesterol and reduces homocysteine levels.
Who Should Take It?
NAC is an excellent choice for those looking for a single supplement to promote overall health including cellular protection and cardiovascular health. People suffering from chronic respiratory conditions may also benefit from regular use of NAC.
Take 1 capsule per day, or as directed by a qualified health care practitioner.
De Flora S, Grassi C, Carati L. (1997). Attention of influenza symptomatology and improvement of cell-mediated immunity with long-term NAC treatment. Eur. Respir J; 10: 1535-1541.
Flanagan, R. (1991). Use of N-Acetyl cysteine in clinical toxicology. AM.J. Med; 91: 131-9.
Gavish D, Breslow JL. (1991). Lipoproteins (a) reduction by N-acetylcysteine. The Lancet; 337: 203-4.
Lorber A, et al. (1973). Clinical application for heavy metal-complexing potential of N-Acetyl-cystene. J. Clin. Pharmacol; 13: 332-336.
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.